Cara Therapeutics Inc

NASDAQ:CARA  
12.79
-0.55 (-4.12%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)656.08M
Current PE27.51
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.46 Million
Adjusted EPS-$0.52
See more estimates
10-Day MA$14.23
50-Day MA$15.02
200-Day MA$16.20
See more pivots

Cara Therapeutics Inc Stock, NASDAQ:CARA

4 Stamford Plaza, 107 Elm Street, Stamford, Connecticut 06902
United States of America
Phone: +1.203.406.3700
Number of Employees: 80

Description

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.